Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based OnCore Biopharma has entered into a hepatitis B virus (HBV) and liver cancer research collaboration with the Baruch S. Blumberg Institute (Blumberg), the research center of the Hepatitis B Foundation.
Subscribe to our email newsletter
As part of the deal, the two parties will jointly work on projects, based on an overarching research plan, in the HBV and liver cancer fields with funding provided by OnCore.
These joint-projects will include discovery of new HBV targets, identification and development of new therapeutic compound series, new assay development and other technologies for hepatitis B and liver cancer.
In consideration for funding these projects, OnCore has the right to secure royalty-bearing worldwide licenses to Blumberg’s rights for inventions made during the collaboration period.
OnCore chief scientific officer Dr Michael Sofia said: "We believe that continuing to invest in novel therapeutic agents, assays and approaches is critical.
"Blumberg’s research is world-class and an exclusive relationship will help further our shared goal of delivering a curative regimen for hepatitis B patients and add to our growing platform of HBV therapeutics."
OnCore also has the option to increase its funding in order to capture additional projects that may fall outside the initial scope of the three-year deal.
The agreement is renewable at OnCore’s option for an additional three years at the same funding level.